• Market Capitalisation market-capitalisation-info $2,585 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-112 Mln

Akero Therapeutics Inc. (AKRO) Share Price

$19.06

As on 06-Dec-2023 16:00 EST

up-down-arrow $0.744.04%

  • Prev Close info

    $18.32

  • Day's Openinfo

    $18.51

  • Today's Highinfo

    $19.52

  • Today's Lowinfo

    $18.11

  • Today's Volumeinfo

    1,115,762

  • 52 Week rangeinfo

    $11.25 - 58.38

Please wait...

Akero Therapeutics Inc. (AKRO) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Akero Therapeutics (AKRO)
-65.22 30.73 -61.86 -56.70 -12.56 -- --
S&P BSE Sensex*
14.27 7.02 5.53 11.01 15.54 14.51 12.72
#
-- -- -- -- -- -- --
As on 06-Dec-2023  |  *As on 07-Dec-2023  |  #As on
2022
2021
2020
Akero Therapeutics (AKRO)
159.10 -18.02 16.24
S&P BSE Sensex
4.44 21.99 15.75
S&P BSE Sensex
4.44 21.99 15.75

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Akero Therapeutics Inc. (AKRO) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Akero Therapeutics Inc. (AKRO)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Akero Therapeutics Inc. (AKRO)

        Pres, CEO & Director

        Dr. Andrew Cheng M.D., Ph.D.

        Co-Founder, Exec. VP, COO & Sec.

        Dr. Jonathan M. Young J.D., Ph.D.

        Headquarters

        South San Francisco, CA

        FAQs for Akero Therapeutics Inc. (AKRO)

        The total asset value of Akero Therapeutics Inc. (AKRO) stood at $ 365 Mln as on 31-Mar-23

        The share price of Akero Therapeutics Inc. (AKRO) is $19.06 (NASDAQ) as of 06-Dec-2023 16:00 EST. Akero Therapeutics Inc. (AKRO) has given a return of -12.56% in the last 3 years.

        Akero Therapeutics Inc. (AKRO) has a market capitalisation of $ 2,585 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.

        The P/B ratio of Akero Therapeutics Inc. (AKRO) is 6.03 times as on 02-Jun-2023, a 1.37% premium to its peers’ median range of 2.54 times.

        Since, TTM earnings of Akero Therapeutics Inc. (AKRO) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Akero Therapeutics Inc. (AKRO) and enter the required number of quantities and click on buy to purchase the shares of Akero Therapeutics Inc. (AKRO).

        Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

        The CEO & director of Dr. Andrew Cheng M.D., Ph.D.. is Akero Therapeutics Inc. (AKRO), and CFO & Sr. VP is Dr. Jonathan M. Young J.D., Ph.D..

        The promoters of Akero Therapeutics Inc. (AKRO) have pledged 0% of the total equity as on Apr-23.

        Akero Therapeutics Inc. (AKRO) Ratios
        Return on equity(%)
        -32.64
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0.08
        Dividend yield(%)
        0

        No, TTM profit after tax of Akero Therapeutics Inc. (AKRO) was $-112 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $2,585.36 Mln
        • Revenue (TTM)revenue-information $0.00 Mln
        • Earnings (TTM) earning-information $-111.84 Mln
        • Cash date-information $343.22 Mln
        • Total Debt info $26.04 Mln
        • Insider's Holding 8.30%
        • Liquidity liquidity High
        • 52 Week range week-range $11.25 - 58.38
        • Shares outstanding share-outstanding 55,325,500
        • 6 Years Aggregate:

          CFO: $-288.03 Mln

          EBITDA: $-419.70 Mln

          Net Profit: $-415.96 Mln

        About The Company

        • IPO Date 20-Jun-2019
        • Pres, CEO & Director Dr. Andrew Cheng M.D., Ph.D.
        • Co-Founder, Exec. VP, COO & Sec. Dr. Jonathan M. Young J.D., Ph.D.
        • Listing key-listing NASDAQ: AKRO
        • Country United States
        • Headquarters headquarters South San Francisco, CA
        • Website website https://www.akerotx.com
        • Business

          Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its...  lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon